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The oncogene GLI1 is involved in the formation of
basal cell carcinoma and other tumor types as a result of
the aberrant signaling of the Sonic hedgehog-Patched
pathway. In this study, we have identified alternative
GLI1 transcripts that differ in their 5* untranslated re-
gions (UTRs) and are generated by exon skipping. These
are denoted a-UTR, b-UTR, and g-UTR according to the
number of noncoding exons possessed (three, two, and
one, respectively). The a- and b-UTR forms represent the
major Gli1 transcripts expressed in mouse tissues,
whereas the g-UTR is present at relatively low levels but
is markedly induced in mouse skin treated with 12-O-
tetradecanoylphorbol 13-acetate. Transcripts corre-
sponding to the murine b and g forms were identified in
human tissues, but significantly, only the g-UTR form
was present in basal cell carcinomas and in proliferat-
ing cultures of a keratinocyte cell line. Flow cytometry
analysis determined that the g-UTR variant expresses a
heterologous reporter gene 14–23-fold higher than the
a-UTR and 5–13-fold higher than the b-UTR in a variety
of cell types. Because expression of the g-UTR variant
correlates with proliferation, consistent with a role for
GLI1 in growth promotion, up-regulation of GLI1 ex-
pression through skipping of 5* noncoding exons may be
an important tumorigenic mechanism.
GLI1 was originally isolated as a highly amplified gene in a
malignant glioma (1) and subsequently implicated in the de-
velopment of other tumor types, including liposarcoma, rhab-
domyosarcoma, osteosarcoma, and astrocytoma (2, 3). Later it
was shown that GLI1 encodes a transcription factor that is a
downstream nuclear component of the Sonic hedgehog-Patched
signaling pathway (4–6). This pathway is evolutionarily con-
served and found to operate in a number of tissues during
vertebrate development and especially in regions involving me-
soderm-ectoderm interactions (7–10). Intercellular signaling
by this pathway is initiated when Sonic hedgehog (a secreted
protein) binds to Patched (a cell surface transmembrane pro-
tein), resulting in the activation of GLI1 in the nucleus and
subsequent expression of target genes. Overexpression of Sonic
hedgehog has been shown to up-regulate Gli1 in chick limb
buds and in the epidermal ectoderm of frog embryos (11, 12),
whereas Gli1 expression is undetectable in Sonic hedgehog null
mouse embryos (13, 14), confirming that Sonic hedgehog sig-
naling regulates Gli1 expression.
The discovery of Patched mutations in familial and sporadic
forms of basal cell carcinoma (BCC),1 the most common skin
cancer, has associated aberrant signaling of the Sonic hedge-
hog-Patched pathway with the formation of these tumors (15–
17). The genetic data are supported by experimental evidence
showing that overexpression of Sonic hedgehog and other com-
ponents of this pathway results in the induction of BCCs in
transgenic mice and transgenic human skin (18–20). Overex-
pression of GLI1 in the epidermis of transgenic animal models
produces BCC-like lesions (21, 22) and will transform rodent
epithelial cells in cooperation with adenovirus EIA (23), indi-
cating that unregulated expression of GLI1 is oncogenic. Re-
cent studies have shown that GLI1 expression is greatly in-
creased in BCCs but not in the surrounding normal tissue,
consistent with a central role in tumor formation (21, 24, 25).
In addition to GLI1, two other isoforms have been identified
in vertebrates (termed GLI2 and GLI3), each encoded by a
separate gene (8, 10). The GLI genes are highly expressed
during development, and their expression profiles correlate
with organogenesis but show only low-level expression in most
adult tissues (7, 9, 10). In the skin, GLI1 expression is readily
observed in the epidermal compartment of the developing hair
follicle, whereas GLI2 and GLI3 transcripts are detected in the
surrounding mesenchyme (10, 21, 25). The role of each GLI in
mediating the Sonic hedgehog signal is not yet clear, but recent
gene ablation studies have shown overlapping roles and indi-
cated some functional redundancy (26, 27). A number of studies
have indicated that GLI1 is a transcriptional activator,
whereas GLI2 and GLI3 can act as both activators and repres-
sors depending on specific post-translational modifications
(28–30). Interestingly, GLI2 and GLI3 are now thought to
regulate GLI1 transcription directly by binding to the GLI1
promoter (28, 30).
The 59 untranslation region (UTR) has a large influence on
translation and plays a key role in post-transcriptional gene
regulation (31–36). The efficiency of translation initiation is
largely governed by the composition and structure of the 59
UTR of the mRNA, which is determined by both its length and
its sequence. Extensive secondary structures and one or two
small upstream open reading frames (uORFs) within a 59 UTR
can profoundly inhibit protein translation. Most highly ex-
pressed mRNAs have relatively short (20–100 nucleotides) 59
UTRs that lack uORFs and extensive secondary structures (for
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teins, growth factors, transcription factors, and other regula-
tory proteins are poorly translated and often have long, highly
structured 59 UTRs with multiple upstream ATGs (32, 35, 36).
In this study, we have identified alternative 59 UTRs of GLI1
transcripts in mouse and human tissues, which are generated
by exon skipping and have marked differences in translation
efficiency. Until now, post-transcriptional regulation of GLI1
has been inferred (37), but a precise mechanism has not been
determined. Our results suggest that post-transcriptional reg-
ulation of GLI1 is mediated by exon skipping and show an
association of the most efficiently translated 59 UTR transcript
with BCC.
EXPERIMENTAL PROCEDURES
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), 59
Rapid Amplification of cDNA Ends (RACE), and PCR—Skin, brain,
heart, kidney, liver, lung, muscle, stomach, spleen, testis, and tongue
were obtained from various strains of neonatal, juvenile, and adult
mice. Total RNA was isolated from these tissues using TRI Reagent
(Molecular Research Center). First-strand cDNA was synthesized from
5 mg of total RNA primed with oligo(dT)16 (PerkinElmer) or random
hexamers (CLONTECH) using Superscript II reverse transcriptase
(Life Technologies) in a total volume of 20 ml. One-tenth by volume of
the cDNA was used as the template for subsequent PCR reactions.
Primer pairs (listed in Table I) for mouse GLI1 corresponding to se-
quences within exon 1 (mGliF1) and exon 2 (mGliR2) and for human
GLI1 corresponding to exon 1 (hGliF1) and 2 (hGliR2) sequences were
used. Each PCR reaction was repeated at least three times with differ-
ent RNA preparations and included negative controls for each set of
reactions. For 59 RACE, we used a cDNA template that was generated
using the primer RACE1 and C tailed using terminal transferase ac-
cording to the manufacturer’s protocol (Life Technologies). PCR was
performed using the RACE anchor and adapter primers (Life Technol-
ogies) and the GLI1-specific nested primer RACE2. Mouse genomic
DNA was amplified using primers derived from exon 1a (mGliF1a) and
exon 2 (mGliR2) sequences. All PCR products were separated on
0.8–2% agarose gels and visualized with ethidium bromide. Separated
fragments were purified using QIAEX II (Qiagen) and sequenced di-
rectly using the Big Dye termination kit and automated fluorescent
sequencing on an ABI-Prism 377 DNA sequencer (PerkinElmer).
12-O-Tetradecanoylphorbol 13-acetate (TPA) Treatment of Mouse
Skin—Neonatal and 7-day-old mice (Swiss outbred) were treated with
20–50 ml of 100 mg/ml TPA (Sigma) topically applied to back skin. Mice
were killed at different time points (0, 3, 8, and 24 h) after application,
and total skin RNA was prepared for RT-PCR as described above.
59 UTR-Green Fluorescent Protein (GFP) Constructs and Functional
Analysis of 59 UTRs—Each of the three alternative 59 UTRs of mouse
GLI1 was generated by RT-PCR using primers mGliF1Nhe and
mGliQR2Age (Table II) that contain NheI and AgeI restriction sites,
respectively. PCR products were gel purified and cloned into the
pGEM-T Easy vector (Promega). The four ATG codons of the a-UTR
were mutated sequentially using the QuikChange site-directed muta-
geneis kit (Stratagene) and complimentary primers mGliMF1–4 and
mGliMR1–4 (Table II). The g-UTR sequence was multimerized using
primers mGliF1Bam and mGliR2Bgl that contain BamHI and BglII sites,
respectively. The amplified fragment was cloned into pGEM-T Easy and
sequenced, and the insert was released by digestion with BamHI and
BglII. The purified fragment was ligated in the presence of both restric-
tion enzymes to form similarly oriented concatomers that were then
used as templates for PCR amplification using mGLiF1Nhe and
mGliR2Age. The products of this reaction were sized on an agarose gel
and the band corresponding to four copies of the g-UTR cloned into the
pGEM-T Easy vector. All inserts were verified by sequence analysis,
released from the pGEM-T Easy vector by restriction digestion with
NheI and AgeI, and subcloned into the corresponding sites of the GFP
expression vector pEGFP-N1 (CLONTECH).
HaCaT, a human keratinocyte cell line (38), Cos-1 (39), and BHK-21
(40) cells were cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum, ampicillin, and streptomycin (Life
Technologies). Primary mouse skin fibroblasts were obtained from new-
born Swiss mice using an established protocol. Briefly, skin was re-
moved, washed in PBS, and incubated in 2.5% dispase (Life Technolo-
gies) for 24 h at 4 °C. The dermis was separated from the epidermis and
incubated in 0.2% collagenase (Sigma) at 37 °C for 1 h. Cells were then
pelleted, washed in PBS, and cultured in Dulbecco’s modified Eagle’s
medium as described above. Primary fibroblasts were used within the
first 2 weeks of culturing.
Transient transfection of GFP constructs was performed using Lipo-
fectAMINE Plus reagent (Life Technologies) according to the manufac-
ture’s instructions. Cells were seeded on round, glass coverslips in
24-well (fluorescence microscope study) or 6-well (flow cytometry study)
plates 24 h before transfection and incubated at 37 °C to a density of
;50–70% confluence. Cultures were washed twice in serum-free media
and then incubated in DNA-LipofectAMINE Plus complexes in OPTI-
MEM (Life Technologies) for 3 h at 37 °C. Dulbecco’s modified Eagle’s
medium containing serum was then added to the culture. One day later,
cells were fixed for microscopy or harvested for flow cytometry analysis.
Twenty thousand cells per sample were analyzed on a FACSCalibur
(Becton Dickinson) cell sorter, using CELLQuest software (Becton
Dickinson).
RESULTS
Identification of Alternative Mouse GLI1 59 UTRs—To iden-
tify the transcriptional start site of the mouse GLI1 gene, 59
RACE was performed on total skin RNA from a BALB/c mouse,
and the resulting PCR product was sequenced directly. This
analysis showed that sequences around the translation start
codon and at the beginning of the transcript were identical to
the published mouse GLI1 sequence obtained from F9 cells
(41). However, the RACE product also contained an additional
119 bases, not present in the published sequence, located at the
splice junction between exons II and III as numbered by Liu et
al. (41). We named this new 59 UTR variant a-UTR and the
published sequence b-UTR (Fig. 1A). To search for other pos-
sible splicing variants, RT-PCR was conducted using a forward
primer located at exon 1 and a reverse primer that hybridizes
FIG. 1. Sequence, exon composition, and pre-mRNA structure
of the alternative 5* UTRs of mouse Gli1. A, sequence alignment of
the three alternative GLI1 59 UTR variants (denoted a-, b-, and g-UTR)
expressed in mouse. The novel 119-base pair sequence of exon 1a is
shown in bold lowercase letters. The ATG codons denoting the beginning
of uORFs are underlined, and the main ORF encoding Gli1 is shown in
bold uppercase letters. The intron-exon boundaries are indicated by
arrows. B, schematic showing the exon composition of the alternative 59
UTRs and the organization of the pre-mRNA from which they are
derived. Exons are denoted by open boxes, and introns are denoted by
solid lines with intron size shown. The translation start site (ATG) of
the main ORF is located in exon 2 and indicated by a bent arrow.
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immediately 59 of the GLI1 ATG codon (Table I). This PCR
revealed a much smaller product, which was sequenced directly
and found to consist of only one 59 noncoding exon. This alterna-
tive mouse GLI1 variant corresponds in both size and sequence to
the published human transcript obtained from a glioma cell line
(7, 41) and was denoted the g-UTR variant (Fig. 1A).
To determine how these alternative transcripts were gener-
ated, we examined the genomic organization of this region.
Mouse genomic DNA was amplified using the primer pair
mGliF1a and mGliR2 (Table I). Sequence analysis of the 2.8-
kilobase product identified the novel 119-nucleotide sequence
within the a-UTR variant as an authentic exon (which we
denoted exon 1b) that is flanked by 2.5 kilobases (intron Ia) and
115 bases (intron Ib) of intervening sequences (Fig. 1B). The
identification of this additional noncoding exon required a
change in the nomenclature used in the earlier study by Lui et al.
(41), with exon II becoming exon 1a and exon III (which encodes
the translation start site) renumbered exon 2 (see Fig. 1B).
Expression of Mouse GLI1 59 UTRs—The expression of the
alternative 59 UTR variants was determined in neonatal, juve-
nile, and adult tissues from various mouse strains by RT-PCR
(Fig. 2). This analysis revealed that the UTR variants had no
particular tissue-specific expression pattern but did show
marked strain-specific differences. In all tissues examined the
larger UTR forms (a- and b-UTR) predominate, whereas the
g-UTR appears as a minor amplified product (Fig. 2A). In some
strains, such as BALB/c, DBA, and C57BL/6, the a-UTR vari-
ant was the major form, whereas in CD1 and SV129 strains,
the b-UTR form was the predominant transcript (Fig. 2B). In
Swiss outbred mice, expression of the a- and b-UTR was het-
erogeneous, with some animals expressing both forms and oth-
ers expressing only one (data not shown). In a given individual,
the expression profile of the two larger transcripts was identi-
cal in all tissues examined irrespective of the strain used (Fig.
2A). We also followed the expression of the UTR variants in
postnatal skin development and found that the apparent levels
of all GLI1 transcripts were reduced with increasing age and
that the g-UTR transcript was not detected at all in adult skin
(data not shown).
To evaluate whether the expression of these 59 UTR variants
correlated with proliferative status, newborn and 7-day-old
animals were treated with TPA topically applied to back skin.
These experiments revealed that expression of the larger UTR
transcripts was maximally reduced at 3 h after application,
whereas expression of the g form was increased (Fig. 3). Re-
duced expression of the a- and b-UTRs was still evident, albeit
not as marked, 24 h after application (data not shown). Because
acute TPA treatment results in increased mitotic activity of
basal layer keratinocytes (42), these data indicate an associa-
tion of the g-UTR transcript with proliferation and the a- and
b-UTRs with differentiation.
Identification of Alternative Human GLI1 59 UTRs—We next
searched for alternative human GLI1 transcripts in newborn
foreskin by RT-PCR with primers derived from exons 1 and 2
(Table I) of the published sequence (7). Two PCR products were
generated and sequenced, with the smaller fragment corre-
sponding to the published sequence (7) and the larger contain-
ing an additional 144 bases located at the splice junction of
exons 1 and 2 (Fig. 4A). The larger transcript was termed
b-UTR, and the smaller sequence was termed the g-UTR var-
iant (Fig. 4, A and B). Notably, the novel 144-nucleotide se-
quence found within the human b-UTR has significant homol-
ogy with mouse exon 1a but is 30 bases larger and contains two
additional ATG codons (Fig. 4C).
The b- and g-UTRs were also present in a brain sample, and
their identity was confirmed by sequence analysis (Fig. 5). The
expression of the b- and g-UTRs was further examined in
HaCaT cells and seven BCC samples. We found that the g
transcript was present in proliferating cultures of HaCaT cells
and all BBC samples, but in contrast to foreskin keratinocytes
and brain tissue, we were unable to amplify the b transcript
from these mRNAs (Fig. 5). Therefore, the g-UTR transcript
may represent the major variant expressed by proliferating
cells in human tissues as well.
Functional Analysis of the GLI1 59 UTRs—The 59 UTR is
known to regulate gene expression by influencing the efficiency
of translation. An examination of the GLI1 59 UTR variants
revealed three small uORFs in mouse a-UTR, two in human
b-UTR, one that overlaps the GLI1 ORF in the mouse b-UTR,
and none in the g-UTRs (Table III). The secondary structure for
each 59 UTR was analyzed using the RNA folding prediction
program MFOLD (43). This program predicted extensive sec-
ondary structures in the longer UTRs, with calculated free
energy values of 272.7 to 294.5 kcal/mol for the mouse a-UTR,
265 kcal/mol for the human b-UTR, and 255 kcal/mol for the
mouse b-UTR. The human and mouse g-UTRs were predicted
not to form stable secondary structures and to have free energy
values of 212 kcal/mol (Table III). The presence of uORFs and
stable secondary structures in the larger UTRs suggests that
they will be less efficiently translated than the g variant, which
lacks these features.
To test the above prediction in vivo, the three mouse GLI1 59
UTR fragments were cloned upstream of a GFP reporter gene
(Fig. 6A), and the constructs were transiently transfected into
HaCaT, Cos-1, and BHK-21 mammalian cell lines and primary
mouse skin fibroblasts. The difference in GFP fluorescence
produced by these constructs was striking (Fig. 6B), with the
TABLE I
Primer sequences 1
Name Locationa Nucleotide sequence
mGliF1 exon 1, mouse agtttccagccctggaccacg
mGliR2 exon 2, mouse ggcgtctcagggaaggatgag
hGliF1 exon 1, human agactccagccctggaccgcg
hGliR2 exon 2, human ggcgtctcagaggagggtgtg
RACE1 Exon 4, mouse gaggtgggaatcctaaag
RACE2 Exon 2/3, mouse ccagaaagtccttctgttcccatgctgg
mGliF1a exon 1a, mouse ctctccctttcttgaggttgg
a Exons are numbered according to Figs. 1B and 4B.
FIG. 2. The expression of alternative GLI1 5* UTRs is not tissue
specific but does show strain variation. RT-PCR was performed on
mRNA isolated from brain (Br), liver (Li), Lung (Lu), skin (Sk), stomach
(St), and tongue (To) tissues of a postnatal mouse (A). A signal for the
b- and g-UTR variants is also present in all tissues examined but is
barely discernible. B, in BALB/c, DBA, and C57Bl/6 strains, the a-UTR
variant is the major transcript (BALB/c is shown in lane 1), whereas the
b-UTR variant is the dominant transcript in CD-1 and SV129 strains
(CD-1 is shown in lane 2). M, DNA marker.
FIG. 3. Expression of the GLI1 5* UTR variants is altered by
TPA treatment. The expression of the g-UTR transcript is increased,
whereas expression of the a-UTR is reduced, in TPA-treated skin (1)
relative to control skin (2). M, DNA size marker.
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a-UTR construct producing the lowest fluorescence levels, the
b-UTR construct producing intermediate levels, and the g var-
iant producing the highest levels (even higher than the GFP
vector control). Importantly, there was no apparent difference
in the transfection efficiency of these constructs for a given cell
type, showing that the increase in the number of brightly
fluorescing cells transfected with the g form is caused by an
increase in GFP production.
To quantify these results, cells were also subjected to flow
cytometry analysis (Fig. 7A). The advantages of this technique
over enzymic reporter assays are that GFP levels are deter-
mined in individual cells using a large number of cells (20,000
cells/construct), and untransfected cells are discarded from the
calculations, thus removing any bias attributable to transfec-
tion efficiencies. This analysis revealed that the a- and b-UTRs
expressed the reporter 60–90% lower than the GFP vector
control, whereas the g-UTR produced 2–3-fold enhancement of
expression (Fig. 7B). Comparison of expression levels between
the three variants reveals a 14–23-fold increase in GFP pro-
duction by the mouse g-UTR construct over the a-UTR (g/a)
and a 5–13-fold increase over the b-UTR (g/b; Fig. 7C). The
greatest differences in GFP intensities were seen in HaCaT
cells. These data show that the g-UTR facilitates expression of
a heterologous protein, whereas the a- and b-UTRs signifi-
cantly suppress protein production.
To determine whether this suppression is caused by the
presence of uORFs or some other property of the longer UTRs,
such as increased secondary structure, we made two additional
constructs. The uORFs of the a-UTR variant were removed by
mutating all four upstream ATG codons to TTG. Significantly,
the mutant a-UTR construct expressed the reporter at levels
that approached that of the g-UTR construct (Fig. 8). To ascer-
tain whether the length of the UTR sequence could influence
expression levels, we produced a g-UTR multimer containing
four copies of this sequence in the same orientation. The g-UTR
multimer, which contained 314 base pairs compared with the 307
base pairs of the a- variant, produced GFP levels that were only
marginally lower than a single copy of the g-UTR (Fig. 8). Taken
together, these data show that the uORFs of the Gli1 UTRs
play a major role in the suppression of protein production.
DISCUSSION
The expression of alternative mRNAs from a single gene is
an important mechanism for gene regulation and for the gen-
eration of functionally different proteins (44, 45). In this study,
we have identified alternative GLI1 transcripts that differ in
their 59 UTRs and are generated by exon skipping. The longer
transcripts (a and b in mouse and b in human) were present in
all normal tissues examined, whereas the shortest transcript
(g-UTR) was present in neonatal tissues but rarely detected in
adult tissues. Significantly, the g form is the only variant found
in BCCs and in a proliferating human keratinocyte cell line.
Moreover, expression of the g form could be induced by TPA
treatment of mouse skin. We have found that the GLI1 59 UTRs
determine the expression levels of a heterologous coding se-
quence in transfected cells, with the g form associated with the
highest levels of expression and the a- and b-UTRs associated
with significantly lower levels. These findings suggest that
GLI1 levels may be regulated through the use of alternative 59
UTRs and predict that an unregulated increase in the g tran-
script over the a and b forms may be tumorigenic.
We initially examined several tissues from various strains of
mice, both neonatal and adult, for evidence of tissue-specific
expression of the GLI1 alternative transcripts. We found that
expression of these transcripts did not show tissue specificity,
but the levels of the a and b transcripts (relative to each other)
did vary between strains. Because BALB/c mice predominantly
FIG. 4. Sequence, exon composition, and pre-mRNA structure
of alternative human GLI1 5* UTRs. A, sequence alignment of the
alternative GLI1 59 UTR variants identified in human tissues (denoted
b- and g-UTR). The novel 144-base pair sequence of exon 1a is shown in
bold lowercase letters. The ATG codons denoting the beginning of
uORFs are underlined, and the main ORF encoding GLI1 is shown in
bold uppercase letters. The intron-exon boundaries are indicated by
arrows. B, schematic showing the exon composition of the alternative 59
UTRs and the organization of the pre-mRNA from which they are
derived. Exons are denoted by open boxes, and introns are denoted by
solid lines with intron size shown. The translation start site (ATG) of
the main ORF is located in exon 2 and indicated by a bent arrow. C,
comparison of human exon 1a sequences with mouse exon 1a. p, iden-
tical bases.
FIG. 5. Detection of human GLI1 5* UTR variants by RT-PCR.
RT-PCR results from skin, brain, the HaCaT human keratinocyte cell
line (HaC), two BCC biopsies, and a no-RNA control (dH2O) are shown.
M, DNA size marker.
TABLE II
Primer sequences 2
Names Nucleotide sequencea
mGliF1Nhe gctagcagtttccagccctggaccacg
mGliR2Age accggtggcgtctcagggaaggatgag
mGliF1Bam ggatccagtttccagccctggaccacg
mGliR2Bgl agatctggcgtctcagggaaggatgag
mGliMF1 tcttgaggttgggttgaagaagcagtt
mGliMR1 aactgcttcttcaacccaacctcaaga
mGliMF2 cccactctttgggttgtttcttcttaa
mGliMR2 ttaagaagaaacaacccaaagagtggg
mGliMF3 gttattgatttccttgaccagtttctg
mGliMR3 cagaaactggtcaaggaaatcaataac
mGliMF4 accagtttctgagttgagggttagagg
mGliMR4 cctctaaccctcaactcagaaactggt
a Primers mGliF1Nhe and mGliR2Age and mGliF1Bam and mGliR2Bgl
are identical to mGliF1 and mGliR2 (Table I) but include restriction
sites for NheI, AgeI, BamHI, and BglII, respectively (bold). The point
mutations (A3 T) introduced by primers mGliMF1–4 and mGliMR1–4
are underlined.
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express the a form and CD1 mice predominantly express the b
form, we sequenced the intron-exon boundaries of this region in
these strains and found them to be identical (data not shown),
suggesting that the expression differences between strains was
not caused by polymorphic variation at these sites. Whether
these strain differences were caused by polymorphic differ-
ences in intronic cis-acting elements or by differences in trans-
acting factors remains to be determined. We did not observe
any transcripts equivalent to the mouse a-UTR in the human
tissues examined, and we were unable to find sequences equiv-
alent to mouse exon 1b in the human gene, suggesting that
humans do not have the capacity to express an a-UTR variant,
although the presence of three upstream ATG codons in exon
1a of the human message compared with just one in mouse,
together with the increased stability of the human b-UTR
(Table III), appears to compensate for the lack of exon 1b
sequences in the human sequence. However, we cannot exclude
the possibility that expression of the a-UTR variant may be
idiosyncratic in human as it is in mice because of the small
sample size that was available in this study.
The expression of the 59 UTR variants did show an apparent
correlation with proliferative status. The longest transcripts
are expressed in normal tissues but not in BCCs or in a human
keratinocyte cell line, whereas the shortest transcript is the
only variant present in BCCs and in HaCaT cells. In addition,
expression of the g form was induced by TPA treatment of
mouse skin, whereas the levels of the longer transcripts were
concomitantly reduced. These observations suggest an associ-
ation of the shortest 59 UTR with actively proliferating kerati-
nocytes and the a and b transcripts with quiescent cells. The
association of the most actively translated transcript with pro-
FIG. 6. The Gli1 5* UTR variants differentially express a GFP
reporter construct in transfected cells. A, diagram showing the
GFP constructs used in the transfection studies. The mouse Gli1 59
UTR sequences were cloned upstream of the GFP ORF as indicated.
pEGFP-N1, parent GFP construct. B, GFP fluorescence observed in
Cos-1 cells transfected with the GFP expression vector alone (GFP) and
a-UTR-GFP (a), b-UTR-GFP (b), and g-UTR-GFP (g) constructs. Trans-
fection efficiency was determined by counting GFP-expressing cells,
which revealed that each construct was transfected with the same
efficiency (within experimental limits).
FIG. 7. Flow cytometry analysis of 5* UTR-GFP constructs in transfected cells. A, fluorescence intensity histogram compiled from the
analysis of 20,000 cells per sample for each construct (see Fig. 6) in transfected Cos-1 cells. The peak closest to the vertical axis is attributable to
untransfected cells (negative cells), which show low fluorescent intensities because of autofluorescence. The second peak represents fluorescence
from transfected cells that express GFP. The four histograms representing each GFP construct were merged to allow direct comparison of
fluorescence intensities. This analysis revealed that the g-UTR construct produced the highest GFP intensities (mean value, 1.045 3 103) and the
a-UTR produced the lowest (mean value, 6.2 3 101). B, graphical representation of GFP intensities of the 59 UTR variants relative to the empty
GFP vector (defined as 100) in transfected BHK-21 (BHK), Cos-1, and HaCaT cells. C, graphical representation of the ratios of GFP intensities
among 59 UTR variants in the cell lines indicated. The g-UTR/a-UTR (f g/a) and g-UTR/b-UTR (M g/b) ratios are shown for constructs transfected
into BHK-21 cells (BHK), Cos-1 cells, primary mouse skin fibroblasts (MSF), and HaCaT cells. The largest differences in GFP fluorescence between
the g-UTR and the a- and b-UTR variants were observed in HaCaT cells. The values shown are the averages of three independent transfection and
cell sorting experiments.
FIG. 8. Flow cytometry analysis of mutant 5* UTR-GFP con-
structs in transfected cells. A graphical representation of GFP in-
tensities of wild-type a-UTR (a), mutant a-UTR (amut), wild-type g-UTR
(g), and the 4-mer g-UTR (gx4) constructs relative to the empty GFP
vector in Cos-1 cells is shown. The values shown are the averages of
three independent transfection and cell-sorting experiments.
TABLE III
Theoretical analysis of GLI1 59 UTRs
59 UTRs uATGsa uORFsb Size of uORFs(no. of codons) Free energy
c
Kcal/mol
Mouse a-UTR 4 3 26,4,10 273 to 295
Mouse b-UTR 1 1 38 ;255
Mouse g-UTR 0 0 — ;212
Human b-UTR 3 2 4, 8 ;265
Human g-UTR 0 0 — ;212
a Number of ATG codons present upstream of the authentic transla-
tion start site.
b Number of ORFs found upstream of the authentic translation start
site. Note that only the uORF in mouse b-UTR overlaps with the main
GLI1 ORF.
c The mean free energy values are indicated for each UTR except for
mouse a-UTR, for which the lowest and highest values are given. These
were calculated using MFOLD (43).
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liferation fits neatly with the observation of increased GLI1
expression in BCCs and with experimental in vivo data show-
ing overexpression of GLI1 resulting in BCC-like lesions (21,
22, 24, 25). The concomitant reduction in a and b transcripts
with increased levels of the g form after TPA treatment is
consistent with a post-transcriptional modification of a single
pre-mRNA species. Although the precise mechanism is un-
known, the activity of transacting factors that control alterna-
tive splicing decisions have been shown to be modulated by
mitogens such as TPA (46–49). It can also be reasoned that
alternative splicing of the GLI1 message may be regulated by
Sonic hedgehog signaling. We are currently testing the possi-
bility that unregulated signaling of the Sonic hedgehog-
Patched pathway (as occurs in BCCs) results in the generation
of increased levels of the g form through changes in the com-
position of splicing factors bound to the nascent GLI1
pre-mRNA. It is also conceivable that tumor-causing mutations
could occur in the splice sites of upstream noncoding exons that
would enhance the formation of the g form. Alternatively, mu-
tations that alter the regulation of factors involved in splice site
selection may also contribute to tumor formation. In addition,
GLI1 has been shown to bind RNA directly at a conserved motif
that is distinct from the GLI DNA binding cis-element and to
regulate translation of the bound mRNA (37, 50). Because
these putative GLI binding motifs are present in the
pre-mRNA sequence of GLI1, an intriguing possibility is that
GLI1 itself or a related protein may determine exon selection.
Two recent reports have indicated that GLI2 and GLI3 tran-
scriptionally regulate GLI1 by binding directly to promoter
sequences, but the same data do not preclude up-regulation of
GLI1 via a post-transcriptional mechanism by these factors as
well (28, 30).
Our results suggest that the a- and b-UTR variants contain
potent translation inhibitors and are in agreement with other
studies showing that 59 UTRs with uORFs and stable second-
ary structures are features of poorly translated mRNAs (31–
36). Furthermore, we have shown that the uORFs present in
the a- and b-UTRs play an important role in mediating this
inhibition. The increased GFP levels observed for the g form
may be wholly attributable to the lack of uORFs, because
increasing the length of the g-UTR variant 4-fold only margin-
ally decreased GFP levels. However, it is also possible that the
g-UTR transcript may be more stable than the longer variants
and consequently is able to produce more product per tran-
script than the a- and b-UTR variants. Several studies have
shown that impaired translation can initiate mRNA decay and
that both stem-loop structures and uORFs within 59 UTRs can
modulate mRNA stability (51). Regardless of whether these
sequences modulate translation efficiency or mRNA stability
(or both), the retention or skipping of 59 noncoding exons gen-
erates alternative UTRs that differentially express a heterolo-
gous reporter, and it is assumed of GLI1 as well. In conclusion,
this study suggests that alternative splicing is an important
mechanism in the regulation of this gene, which may in part
contribute to the up-regulation of GLI1 observed in BCCs.
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